Pro-CME showcases the best-in-class online continuing medical education programs developed for physicians, nurses, and healthcare professionals. We partner with leading medical and healthcare organizations to bring you top CME activities aimed at improving patient care and clinical outcomes. With a variety of multimedia program formats across 29 specialties, Pro-CME provides a destination for clinicians to participate in the latest educational activities for earning credit towards your CME/CE certification.

Spotlight on Pulmonary/Respiratory Medicine

Credits: 0.75 CME
Improving Severe Asthma Control through Comprehensive Patient Assessment and Tailored Treatment Selection
William Busse, MD
Integrity Continuing Education, Inc.

Improving Severe Asthma Control through Comprehensive Patient Assessment and Tailored Treatment Selection

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: November 20, 2018
Expires: November 20, 2019
1 hour to complete

Provided by


Integrity Continuing Education, Inc.

Target Audience

This educational initiative has been designed for allergists, pulmonologists, and otolaryngic allergists involved in the management of patients with severe asthma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Describe clinical criteria for severe asthma and outline an approach to assessing symptom control and disease burden
  • Identify known phenotypes of severe asthma
  • Develop an approach to the treatment of severe asthma that is personalized to the individual patient and describe the most recent clinical data on new and emerging therapies for severe asthma
  • Identify strategies for improving communication to promote collaborative decision-making and the ability to self-manage among patients with severe asthma

Activity Description

Despite recent advances in our understanding of the pathophysiology of asthma and a corresponding expansion of targeted treatment modalities, severe asthma care continues to be a challenge in clinical practice. This program is designed to address this issue by imparting clinical knowledge and competence to clinicians that will promote comprehensive assessment and highly personalized treatment of patients whose symptoms meet the criteria for severe asthma. In addition, this initiative is also targeted at providing clinicians with guidance on strategies for improving disease awareness, increasing collaborative decision-making, and promoting self-management among patients with severe asthma.

Faculty

William W. Busse, MD
Professor of Medicine
Division of Allergy, Pulmonary, and Critical Care Medicine
School of Medicine and Public Health
University of Wisconsin
Madison, Wisconsin


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

William W. Busse, MD
Royalty: Elsevier
Consulting Fees: AstraZeneca Pharmaceuticals LP, Genentech, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Sanofi Genzyme and Regeneron Pharmaceuticals, Teva Pharmaceuticals
Data Monitoring Boards/Study Oversight Committees: Boston Scientific, Genentech, ICON Clinical Research Ltd.

The Integrity CE planners and managers have nothing to disclose.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of November 20, 2018 through November 20, 2019 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Statement of Commercial Support

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Pulmonary/Respiratory Medicine Presentations

0.75 CME
Integrity Continuing Education, Inc.
Exploring Novel Therapies for Scleroderma-Associated ILD: An Evidence-based Approach to Diagnosis and Management

Exploring Novel Therapies for Scleroderma-Associated ILD: An Evidence-based Approach to Diagnosis and Management

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: October 10, 2018
Expires: October 10, 2019
0.75 hour(s) to complete

Provided By

Target Audience

This educational initiative has been designed for pulmonologists, rheumatologists, and internal medicine physicians involved in the care of patients with SSc-ILD.

Learning Objectives

  • Determine the elements of a comprehensive diagnostic workup to achieve timely diagnosis of SSc-ILD and assess patient risk for disease progression
  • Tailor treatment approaches for patients with SSc-ILD based on relevant clinical trial evidence of investigational regimens
  • Outline effective strategies for improving the physician-patient dialogue and collaboration across the multidisciplinary care team to meet the needs of patients with SSc-ILD

Activity Description

ILD is universally recognized as the most serious complication of SSc and has been identified as the leading cause of mortality among patients with SSc-ILD. Despite awareness of the risk for ILD development among patients with SSc, prompt and accurate diagnosis remains challenging due to the lack of accepted protocols for screening and risk stratification, as well as difficulties in distinguishing between systemic manifestations of SSc and exertional dyspnea due to lung involvement.

Traditional treatment approaches have centered upon immunosuppression to target underlying inflammation and autoimmunity. However, with the advent of antifibrotic therapies capable of slowing, or even halting, the progression of IPF, questions have been raised about their potential to similarly impact SSc-ILD progression. While it remains to be determined whether this is indeed the case, studies to address this issue are ongoing. This program will provide clinicians with education that is targeted at helping them to remain informed regarding the current status of these investigations, as well as provide them with the knowledge and skills to provide patients with SSc-ILD with an accurate diagnosis and optimal disease management.

Faculty

Aryeh Fischer, MD
Associate Professor of Medicine
Division of Rheumatology
Division of Pulmonary Sciences &
Critical Care Medicine
Department of Medicine
University of Colorado School of Medicine
Aurora, Colorado


David Lederer, MD
Associate Professor
Department of Medicine
Associate Division Chief
Clinical & Translational Research Director
Advanced Lung Disease Program
Columbia University
New York, New York


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Aryeh Fischer, MD
Consulting Fees: Boehringer Ingelheim, F Hoffman La Roche

David Lederer, MD
Consulting Fees: Roche, Veracyte
Research: Boehringer Ingelheim

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The Integrity CE planners and managers have nothing to disclose.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of October 10, 2018 through October 10, 2019 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Statement of Commercial Support

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Boehringer Ingelheim Pharmaceuticals, Inc. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions about the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.75 CME
Integrity Continuing Education, Inc.
Improving Severe Asthma Control through Comprehensive Patient Assessment and Tailored Treatment Selection

Improving Severe Asthma Control through Comprehensive Patient Assessment and Tailored Treatment Selection

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: November 20, 2018
Expires: November 20, 2019
1 hour to complete

Provided by


Integrity Continuing Education, Inc.

Target Audience

This educational initiative has been designed for allergists, pulmonologists, and otolaryngic allergists involved in the management of patients with severe asthma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Describe clinical criteria for severe asthma and outline an approach to assessing symptom control and disease burden
  • Identify known phenotypes of severe asthma
  • Develop an approach to the treatment of severe asthma that is personalized to the individual patient and describe the most recent clinical data on new and emerging therapies for severe asthma
  • Identify strategies for improving communication to promote collaborative decision-making and the ability to self-manage among patients with severe asthma

Activity Description

Despite recent advances in our understanding of the pathophysiology of asthma and a corresponding expansion of targeted treatment modalities, severe asthma care continues to be a challenge in clinical practice. This program is designed to address this issue by imparting clinical knowledge and competence to clinicians that will promote comprehensive assessment and highly personalized treatment of patients whose symptoms meet the criteria for severe asthma. In addition, this initiative is also targeted at providing clinicians with guidance on strategies for improving disease awareness, increasing collaborative decision-making, and promoting self-management among patients with severe asthma.

Faculty

William W. Busse, MD
Professor of Medicine
Division of Allergy, Pulmonary, and Critical Care Medicine
School of Medicine and Public Health
University of Wisconsin
Madison, Wisconsin


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

William W. Busse, MD
Royalty: Elsevier
Consulting Fees: AstraZeneca Pharmaceuticals LP, Genentech, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Sanofi Genzyme and Regeneron Pharmaceuticals, Teva Pharmaceuticals
Data Monitoring Boards/Study Oversight Committees: Boston Scientific, Genentech, ICON Clinical Research Ltd.

The Integrity CE planners and managers have nothing to disclose.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of November 20, 2018 through November 20, 2019 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Statement of Commercial Support

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

0.50 CME / CNE
AXIS
Using “Rapid Progression” and Response Levels as Prognostic Markers in Selecting Optimal Second-Line Therapy for NSCLC

Using “Rapid Progression” and Response Levels as Prognostic Markers in Selecting Optimal Second-Line Therapy for NSCLC

Start

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credits
0.5 Contact Hour(s)
Released: August 8, 2018
Expires: August 7, 2019
30 minutes to complete

Provided by

This educational activity is provided by

Target Audience

This activity is intended for medical oncologists, thoracic oncologists, pulmonologists, pathologists, oncology nurses, and other healthcare professionals involved in the treatment of NSCLC.

Learning Objectives

At the conclusion of this activity, participants should be better able to:

  • Analyze treatment options for patients with advanced NSCLC that does not have an actionable mutation target and has progressed on or after prior platinum-based therapy
  • Develop treatment plans for patients with advanced NSCLC without targetable activating mutations that has progressed on or after prior platinum-based therapy according to clinical practice guidelines
  • Select appropriate treatment for NSCLC without targetable activating mutations that has progressed rapidly on initial platinum-based therapy

Activity Description

Lung cancer continues to be the leading cause of cancer death in the United States, accounting for 27% of all cancer deaths in males and 25% in females. Non–small cell lung cancer (NSCLC) accounts for approximately 80% of lung cancer cases. The prognosis of patients with NSCLC is poor; the 5-year overall survival (OS) rate is 5% for those with metastatic disease and 18% across all stages. Approximately 70% of patients with lung cancer have advanced or metastatic disease at initial diagnosis.

The discovery of predictive biomarkers, such as sensitizing epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, ROS1 rearrangements, and BRAF mutations has led to an improvement in OS and progression-free survival by identifying subgroups of patients who benefit from targeted treatment. “Although recent advances have improved clinical outcomes for patients with tumors harboring targetable driver mutations, most NSCLC tumors lack these mutations, highlighting the need for novel therapeutic interventions… Patients with advanced NSCLC that is aggressive and rapidly progresses after first-line treatment have a poor prognosis and have been studied in several trials” (Reck et al, 2017).

This activity will review available treatment options, current guideline recommendations, and recent data about disease that has progressed rapidly on initial therapy to inform appropriate treatment selection.

Statement of Educational Need

The goal of this activity is to provide clinicians with the latest advances in the treatment of patients with advanced NSCLC without targetable activating mutations that has progressed on prior platinum-based therapy, including patients with disease that has progressed rapidly on initial therapy.

Faculty

Stephen V. Liu, MD
Associate Professor of Medicine
Lombardi Comprehensive Cancer Center
Georgetown University School of Medicine
Washington, DC


Disclosure of Conflicts of Interest

AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

AXIS will identify, review, and resolve all conflicts of interestthat faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Stephen V. Liu, MD, reported a financial interest/relationship or affiliation in the form of Advisor/Consultant, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Co, Celgene Corp, Genentech/Roche, Ignyta, Lilly USA, Pfizer, Inc, Taiho Pharmaceutical Co, Ltd, Takeda Oncology; Contracted research, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Clovis Oncology, Corvus Pharmaceuticals, Esanex Inc, Genentech, Inc, Ignyta, Lycera, MedImmune, Merck & Co, Inc, OncoMed Pharmaceuticals, Pfizer, Inc, Threshold Pharmaceuticals.

The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The following AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko, BS; Marilyn Haas, PhD, RN, CNS, ANP-BC; and Stephanie Sutphin, PharmD,hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.

Accreditation Statement

In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Designation of Credit

Credit Designation for Physicians
AXIS Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 0.5 contact hours.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Method of Participation and Request for Credit

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 100% and the post-activity evaluation, your certificate will be made available immediately.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

AXIS Contact Information

For information about the certification of this activity, please contact AXIS at info@axismeded.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.